164 related articles for article (PubMed ID: 37497724)
21. Usefulness of controlled attenuation parameter and liver stiffness measurement for detecting increased arterial stiffness in asymptomatic populations in China.
Yu XY; Song XX; Tong YL; Wu LY; Song ZY
Medicine (Baltimore); 2020 Nov; 99(48):e23360. PubMed ID: 33235107
[TBL] [Abstract][Full Text] [Related]
22. FIB-4 is closer to FibroScan screen results to detecting advanced liver fibrosis and maybe facilitates NAFLD warning.
Ding Y; Wang Z; Niu H; Deng Q; Wang Y; Xia S
Medicine (Baltimore); 2023 Aug; 102(34):e34957. PubMed ID: 37653822
[TBL] [Abstract][Full Text] [Related]
23. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening.
Lomonaco R; Godinez Leiva E; Bril F; Shrestha S; Mansour L; Budd J; Portillo Romero J; Schmidt S; Chang KL; Samraj G; Malaty J; Huber K; Bedossa P; Kalavalapalli S; Marte J; Barb D; Poulton D; Fanous N; Cusi K
Diabetes Care; 2021 Feb; 44(2):399-406. PubMed ID: 33355256
[TBL] [Abstract][Full Text] [Related]
24. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
[TBL] [Abstract][Full Text] [Related]
25. ALT poorly predicts Nonalcoholic Fatty Liver Disease (NAFLD) and liver fibrosis as determined by vibration-controlled transient elastography in adult National Health and Nutrition Examination Survey 2017-2018.
Condon S; Hu H; Kong M; Cave MC; McClain CJ
Am J Med Sci; 2024 May; 367(5):310-322. PubMed ID: 38307172
[TBL] [Abstract][Full Text] [Related]
26. Vibration Controlled Transient Elastography in Screening for Silent Liver Diseases.
Said E; Abdel-Gawad M; Abdelsameea E; Elshemy EE; Abdeen N; Elbasiony M; Omran D; Elesnawy Y; Eid A; Lashen SA; Elbahr O; Naguib GG; Afify S; Bahbah EI; Alboraie M
Eur J Gastroenterol Hepatol; 2023 Oct; 35(10):1204-1210. PubMed ID: 37577784
[TBL] [Abstract][Full Text] [Related]
27. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study.
Mikolasevic I; Domislovic V; Turk Wensveen T; Delija B; Klapan M; Juric T; Lukic A; Mijic A; Skenderevic N; Puz P; Ostojic A; Krznaric Z; Radic-Kristo D; Filipec Kanizaj T; Stimac D
Eur J Intern Med; 2020 Dec; 82():68-75. PubMed ID: 32839076
[TBL] [Abstract][Full Text] [Related]
28. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
[TBL] [Abstract][Full Text] [Related]
29. Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV.
Milic J; Menozzi V; Schepis F; Malagoli A; Besutti G; Franconi I; Raimondi A; Carli F; Mussini C; Sebastiani G; Guaraldi G
AIDS; 2020 Nov; 34(13):1915-1921. PubMed ID: 33009010
[TBL] [Abstract][Full Text] [Related]
30. Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery.
Yang A; Nguyen M; Ju I; Brancatisano A; Ryan B; van der Poorten D
Sci Rep; 2021 Jul; 11(1):14006. PubMed ID: 34234198
[TBL] [Abstract][Full Text] [Related]
31. Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Risk-Based Approach to Targeted Screening.
Poustchi H; Alaei-Shahmiri F; Aghili R; Nobarani S; Malek M; Khamseh ME
Arch Iran Med; 2021 Mar; 24(3):177-186. PubMed ID: 33878875
[TBL] [Abstract][Full Text] [Related]
32. The performance of M and XL probes of FibroScan for the diagnosis of steatosis and fibrosis on a Brazilian nonalcoholic fatty liver disease cohort.
Cardoso AC; Cravo C; Calçado FL; Rezende G; Campos CFF; Neto JMA; Luz RP; Soares JAS; Moraes-Coelho HS; Leite NC; Perez RM; Villela-Nogueira CA
Eur J Gastroenterol Hepatol; 2020 Feb; 32(2):231-238. PubMed ID: 31464788
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of non-alcoholic fatty liver disease among patients with non-diabetic chronic kidney disease detected by transient elastography.
Behairy MA; Sherief AF; Hussein HA
Int Urol Nephrol; 2021 Dec; 53(12):2593-2601. PubMed ID: 33675475
[TBL] [Abstract][Full Text] [Related]
35. Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV.
Michel M; Labenz C; Wahl A; Anders M; Armandi A; Huber Y; Galle PR; Sprinzl M; Schattenberg JM
AIDS; 2022 Oct; 36(12):1665-1674. PubMed ID: 35849074
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
[TBL] [Abstract][Full Text] [Related]
37. Association between hypertension and the prevalence of liver steatosis and fibrosis.
Fu H; Yu H; Zhao Y; Chen J; Liu Z
BMC Endocr Disord; 2023 Apr; 23(1):85. PubMed ID: 37081417
[TBL] [Abstract][Full Text] [Related]
38. Comparing 2D-shear wave to transient elastography for the evaluation of liver fibrosis in nonalcoholic fatty liver disease.
Karagiannakis DS; Markakis G; Lakiotaki D; Cholongitas E; Vlachogiannakos J; Papatheodoridis G
Eur J Gastroenterol Hepatol; 2022 Sep; 34(9):961-966. PubMed ID: 35913779
[TBL] [Abstract][Full Text] [Related]
39. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
Woreta TA; Van Natta ML; Lazo M; Krishnan A; Neuschwander-Tetri BA; Loomba R; Mae Diehl A; Abdelmalek MF; Chalasani N; Gawrieh S; Dasarathy S; Vuppalanchi R; Siddiqui MS; Kowdley KV; McCullough A; Terrault NA; Behling C; Kleiner DE; Fishbein M; Hertel P; Wilson LA; Mitchell EP; Miriel LA; Clark JM; Tonascia J; Sanyal AJ;
PLoS One; 2022; 17(4):e0266859. PubMed ID: 35427375
[TBL] [Abstract][Full Text] [Related]
40. Genetic Variants in nicotinamide-N-methyltransferase (NNMT) gene are related to the stage of non-alcoholic fatty liver disease diagnosed by controlled attenuation parameter (CAP)-fibroscan.
Hasan EM; Abd Al Aziz RA; Sabry D; Darweesh SK; Badary HA; Elsharkawy A; Abouelkhair MM; Yosry A
J Gastrointestin Liver Dis; 2018 Sep; 27(3):265-272. PubMed ID: 30240470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
